Cancer & Oncology Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

This Phase 3 trial is exploring whether adding the drug zipalertinib to chemotherapy can help patients with early stage non-small cell lung cancer who have uncommon EGFR mutations after surgery. If successful, this treatment could help prevent the cancer from returning and improve the time patients remain disease-free. The study is currently recruiting adults worldwide with stage IB to IIIA lung cancer who have completed tumor removal.

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

This Phase 4 study is focused on understanding why some breast cancers stop responding to current treatments. It includes patients with different types of breast cancer such as HER2 positive, hormone receptor positive, or triple negative. By analyzing blood and tumor samples, researchers hope to discover new ways to overcome resistance and improve future treatment options. The study is recruiting in several European countries.

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

This Phase 3b trial is testing a targeted drug called trastuzumab deruxtecan in patients with metastatic breast cancer that has low or no HER2 expression. This group currently has limited treatment options, so this study may provide a new therapy to help control cancer growth. The trial is enrolling 250 patients worldwide to evaluate how safe and effective the treatment is for this specific type of breast cancer.

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

This Phase 3 trial is looking at whether hormone therapy combined with radiation can be tailored based on a patient’s gene risk score for prostate cancer. Patients with a low risk score may receive less intense treatment to reduce side effects, while those with a high risk score may get more intensive therapy to improve outcomes. The study is active and includes over 2700 participants in the United States and Canada.

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This Phase 3 trial is investigating whether adding high dose, focused radiation (called SBRT) to standard treatment can better target tumors in patients with locally advanced non-small cell lung cancer. The aim is to improve treatment effectiveness while minimizing harm to healthy tissue. The study is recruiting 474 patients in the US and Canada and includes common chemotherapy, immunotherapy, and targeted therapy options.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.